NVDA gained a massive 197% since our AI first added it in November - is it time to sell? 🤔Read more

Ex-Valeant, Philidor executives get prison for fraud

Published 2018-10-30, 04:57 p/m
© Reuters.  Ex-Valeant, Philidor executives get prison for fraud
SO
-
BHC
-

By Jonathan Stempel

NEW YORK, Oct 30 (Reuters) - A former executive at Valeant Pharmaceuticals International Inc (NYSE:BHC) and the former head of a start-up mail-order pharmacy were sentenced to one year in prison on Tuesday after being convicted of defrauding the drugmaker through a secret kickback scheme.

Gary Tanner, 41, the former Valeant executive, and Andrew Davenport, 50, the former chief executive of Philidor Rx Services LLC, were also ordered to forfeit $9.7 million, representing the alleged kickback.

The sentences were imposed by U.S. District Judge Loretta Preska in Manhattan.

Both defendants had been convicted in May on four charges, including honest services wire fraud and conspiracy to commit money laundering. had recommended prison terms of between 2-1/2 and 10 years for Tanner, and 2-1/2 and eight years for Davenport. The defendants said no prison time was justified.

Lawyers for Tanner did not immediately respond to requests for comment. Sharon McCarthy, a lawyer for Davenport, said her client plans to appeal his conviction, but that the sentence was "extremely fair."

The case was the first criminal prosecution arising from multiple probes into Valeant's business practices, including its ties to the now-defunct Philidor.

Those ties began drawing scrutiny in October 2015, when investors learned that Valeant had in 2014 acquired an option to buy Philidor, and was suspected of using it to boost sales.

The revelations contributed to a steep fall in Valeant's share price that was compounded by the probes and the Laval, Quebec-based company's heavy debt load.

Management was overhauled, and Valeant changed its name to Bausch Health Cos BHC.TO in July, taken from the name of its Bausch & Lomb eye care unit.

Tanner had managed Valeant's relationship with Philidor as well as Valeant's "alternative fulfillment" program, through which the drugmaker sought to increase prescriptions for its own drugs instead of cheaper generic substitutes.

Prosecutors accused Tanner of steering Valeant business to Philidor, while concealing a $9.7 million kickback from Davenport that came from the roughly $50 million Davenport received when Valeant acquired the option to buy his company.

"I deeply regret giving money to Gary Tanner," Davenport told Preska.

Prosecutors said that to keep the scheme secret, Tanner often used an email account with the name "Brian Wilson" to communicate with Davenport and sabotage potential business with rival pharmacies.

"Tanner was entrusted to manage Valeant's relationship with Davenport's company," U.S. Attorney Geoffrey Berman said in a statement. "Instead, they devised a scheme to pillage Valeant and share the proceeds."

The case is U.S. v Tanner et al, U.S. District Court, Southern (NYSE:SO) District of New York, No. 17-cr-00061.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.